Contributions to Global Public Health through Innovative Recombinant Protein Technology
Learn more
InThera Inc. aims to develop and deliver the next generation virus-like
particle (VLP)-based prophylactic and therapeutic vaccines
with an improved efficacy and safety profile against emerging/re-emerging
viral infections of global concern.
InThera Inc. established a novel E. coli –based VLP production platform which offers
efficient, homologous,stable and highly immunogenic products and significantly
reduces scaling-up time and complexity
The endeavor will heighten the translation opportunity for unmet-need vaccines,
as well as providing alternative means for the delivery of safer and more effective
version of previously licensed vaccines
Globally ~700 million cases per year (2016) & A vaccine candidate with a great commercial value due to market
demand in both developing and developed countries
The absence of a norovirus cell culture system & Unfeasible to develop vaccines with conventional methods
-> A novel VLP vaccine can create a large market.
Rotavirus PNP Vaccine
Business plan for Rota Virus vaccine will be developed in two main market sectors. The first will be GAVI,
supporting Low- and Middle-
Income Countries where Global Excess will be placed. The other sector will be largely populated countries with high
Rota virus prevalence.
Outbreaks of emerging and mutant viruses, oversea inflow & the highest potential for pandemic due to climate change
No spontaneous infection in S. Korea
Severe symptoms, Emerging in new regions and increased incidence due to climate change, and fast spreading
InThera INC CEO : Deog-Young Choi B-218, 11, Beobwon-ro 11-gil, Songpa-gu, Seoul, Republic of Korea TEL 82-02-6239-2570